NL-OMON41992撤回3 期
A PHASE III RANDOMIZED TRIAL OF GEMCITABINE PLUS DOCETAXEL FOLLOWED BY DOXORUBICIN V. OBSERVATION FOR UTERUS-LIMITED, HIGH GRADE UTERINE LEIOMYOSARCOMA - EORTC 55116-62114
European Organisation for Research in Treatment of Cancer (EORTC)0 个研究点目标入组 18 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients with a high risk of uterine leiomyosarcoma FIGO stage I.
- •Institutional pathology review of leiomyosarcoma
- •Al patients must be no longer than 12 weeks (3 months) from surgical resection of cancer at the time of enrollment on study.
- •Age > 18 years
- •Written informed consent
排除标准
- •Patient who had prior therapy with docetaxel or gemcitabine or doxorubicine
- •Patient with a history of malignancy being present within the last 5 years
- •Patient with a history of severe hypersensitivity reaction to anthracenedione/anthracyclines or drugs containing polysorbate 80 excipients are not allowed to participate in the study.
研究者
相似试验
进行中（未招募）
1 期
A Phase III Randomised Trial of Gemcitabine plus Docetaxel followed by Doxorubicin versus observation for uterus-limited, high grade uterine leiomyosarcomaPatients with high risk uterine LMS, FIGO stage I (confined to corpus +/- cervix).MedDRA version: 14.1 Level: PT Classification code 10046799 Term: Uterine leiomyosarcoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002852-17-GBEORTC216
进行中（未招募）
1 期
A Phase III Randomized Trial of Gemcitabine plus Docetaxel followed by Doxorubicin v. observation for uterus-limited, High Grade Uterine LeiomyosarcomaPatients with high risk uterine LMS, FIGO stage I (confined to corpus +/-cervix).MedDRA version: 18.1Level: PTClassification code 10046799Term: Uterine leiomyosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002852-17-DKEORTC216
进行中（未招募）
1 期
A Phase III Randomized Trial of Gemcitabine plus Docetaxel followed by Doxorubicin v. observation for uterus-limited, High Grade Uterine LeiomyosarcomaEUCTR2012-002852-17-ESEORTC216
进行中（未招募）
1 期
A Phase III Randomized Trial of Gemcitabine plus Docetaxel followed by Doxorubicin v. observation for uterus-limited, High Grade Uterine LeiomyosarcomaPatients with high risk uterine LMS, FIGO stage I (confined to corpus +/-cervix).MedDRA version: 18.1Level: PTClassification code 10046799Term: Uterine leiomyosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002852-17-BEEORTC216
进行中（未招募）
1 期
A Phase III Randomized Trial of Gemcitabine plus Docetaxel followed by Doxorubicin v. observation for uterus-limited, High Grade Uterine LeiomyosarcomaPatients with high risk uterine LMS, FIGO stage I (confined to corpus +/-cervix).MedDRA version: 20.0Level: PTClassification code 10046799Term: Uterine leiomyosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002852-17-FREORTC216